drugset / Trial / NCT02461043

Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma

NCT02461043 ↗

Phase 3 Unknown 386 enrolled Chinese Academy of Medical Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

Esophageal cancer is a highly aggressive malignancy with a poor overall outcome. * Five year survival rate after radical esophagectomy is modest at about 40%.The patients with regional lymph node metastases have worse outcome than those without lymph node metastases. * No standard postoperative adjuvant chemotherapy has ever been established.

Timeline

Start
2015-04
Primary completion
2020-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 50 mg/m2 Intravenous
Subject Paclitaxel Small molecule 150 mg/m2 Intravenous

Indications